Becton Dickinson and Co (BDX) is Mawer Investment Management Ltd.’s 6th Largest Position
Mawer Investment Management Ltd. trimmed its stake in Becton Dickinson and Co (NYSE:BDX) by 5.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,702,570 shares of the medical instruments supplier’s stock after selling 97,258 shares during the quarter. Becton Dickinson and accounts for 3.0% of Mawer Investment Management Ltd.’s portfolio, making the stock its 6th biggest holding. Mawer Investment Management Ltd. owned about 0.64% of Becton Dickinson and worth $365,192,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently added to or reduced their stakes in BDX. Mission Wealth Management LP purchased a new position in shares of Becton Dickinson and in the fourth quarter worth $359,000. Suntrust Banks Inc. raised its stake in shares of Becton Dickinson and by 2.7% in the fourth quarter. Suntrust Banks Inc. now owns 44,690 shares of the medical instruments supplier’s stock worth $9,566,000 after purchasing an additional 1,185 shares during the last quarter. Harfst & Associates Inc. purchased a new position in shares of Becton Dickinson and in the fourth quarter worth $239,000. Roberts Glore & Co. Inc. IL increased its position in Becton Dickinson and by 8.6% during the fourth quarter. Roberts Glore & Co. Inc. IL now owns 5,909 shares of the medical instruments supplier’s stock valued at $1,265,000 after acquiring an additional 467 shares during the last quarter. Finally, Baird Financial Group Inc. increased its position in Becton Dickinson and by 52.7% during the fourth quarter. Baird Financial Group Inc. now owns 52,429 shares of the medical instruments supplier’s stock valued at $11,223,000 after acquiring an additional 18,084 shares during the last quarter. 83.37% of the stock is currently owned by institutional investors and hedge funds.
In other Becton Dickinson and news, EVP Thomas E. Polen, Jr. sold 1,877 shares of the company’s stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $227.00, for a total transaction of $426,079.00. Following the sale, the executive vice president now directly owns 15,387 shares in the company, valued at $3,492,849. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Timothy M. Ring sold 176 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $218.27, for a total value of $38,415.52. Following the sale, the director now owns 170,688 shares in the company, valued at $37,256,069.76. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 281,108 shares of company stock worth $61,321,396. Company insiders own 1.00% of the company’s stock.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, beating analysts’ consensus estimates of $2.41 by $0.07. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The company had revenue of $3.08 billion during the quarter, compared to analyst estimates of $3.05 billion. During the same period in the prior year, the company earned $2.33 earnings per share. The firm’s revenue was up 5.4% on a year-over-year basis. sell-side analysts forecast that Becton Dickinson and Co will post 10.94 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be paid a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 1.34%. The ex-dividend date of this dividend is Thursday, March 8th. Becton Dickinson and’s payout ratio is presently 120.48%.
BDX has been the subject of a number of research reports. Argus upped their price objective on Becton Dickinson and to $235.00 and gave the company a “buy” rating in a research report on Thursday, December 14th. They noted that the move was a valuation call. Deutsche Bank set a $260.00 price objective on Becton Dickinson and and gave the company a “buy” rating in a research report on Friday, December 29th. Evercore ISI initiated coverage on Becton Dickinson and in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $245.00 price objective for the company. Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price objective for the company in a research report on Wednesday, January 3rd. Finally, KeyCorp started coverage on Becton Dickinson and in a research report on Friday, January 5th. They set an “overweight” rating and a $260.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Becton Dickinson and presently has a consensus rating of “Buy” and a consensus price target of $238.00.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.